New Format and E-Mail Address for Roche Investor Updates

This is to inform you that, as of 20 July 2020, Roche will send its Investor Updates from a new e-mail account with a new format as a joint-release with our Media Relations department.


Please make sure the following e-mail addresses are added to your ‘safe sender’ list:
roche.investor-relations@roche.com and global.news@roche.com.

Do not hesitate to contact us if you have any questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com	Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com	Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com

 

Attachment

• 200706_IR_change_e-mail_en